Effect of clozapine on locomotor activity and anxiety-related behavior in the neonatal mice administered MK-801


Pinar N., AKILLIOĞLU K., Sefil F., Alp H., Sagir M., Acet A.

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol.15, no.3, pp.74-79, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 3
  • Publication Date: 2015
  • Doi Number: 10.17305/bjbms.2015.472
  • Journal Name: BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.74-79
  • Keywords: MK-801, clozapine, open field test, elevated plus maze test, neonatal mice, ELEVATED PLUS-MAZE, ALTERS ADULT BEHAVIOR, PREFRONTAL CORTEX, RECEPTOR BLOCKADE, NMDA, RAT, DOPAMINE, MODEL, ANTAGONISM, BALB/C
  • Çukurova University Affiliated: Yes

Abstract

Atypical antipsychotics have been used to treat fear and anxiety disturbance that are highly common in schizophrenic patients. It is suggested that disruptions of N-methyl-d-aspartate (NMDA)-mediated transmission of glutamate may underlie the pathophysiology of schizophrenia. The present study was conducted to analyze the effectiveness of clozapine on the anxiety-related behavior and locomotor function of the adult brain, which had previously undergone NMDA receptor blockade during a developmental period. In order to block the NMDA receptor, male mice were administered 0.25 mg/kg of MK-801 on days 7 to 10 postnatal. In adulthood, they were administered intraperitoneally 0.5 mg/kg of clozapine and tested with open-field and elevated plus maze test, to assess their emotional behavior and locomotor activity. In the group receiving MK-801 in the early developmental period the elevated plus maze test revealed a reduction in the anxiety-related behavior (p<0.05), while the open-field test indicated a decrease in locomotor activity (p<0.01). Despite these reductions, clozapine could not reverse the NMDA receptor blockade. Also, as an atypical antipsychotic agent, clozapine could not reverse impairment in the locomotor activity and anxiety-related behavior, induced by administration of the MK-801 in neonatal period.